SG10201901695RA - Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers - Google Patents

Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers

Info

Publication number
SG10201901695RA
SG10201901695RA SG10201901695RA SG10201901695RA SG10201901695RA SG 10201901695R A SG10201901695R A SG 10201901695RA SG 10201901695R A SG10201901695R A SG 10201901695RA SG 10201901695R A SG10201901695R A SG 10201901695RA SG 10201901695R A SG10201901695R A SG 10201901695RA
Authority
SG
Singapore
Prior art keywords
elution
mops
biomolecules
mes
mobile phase
Prior art date
Application number
SG10201901695RA
Inventor
Rahul Godawat
Daniel Cummings
Veena Warikoo
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of SG10201901695RA publication Critical patent/SG10201901695RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B50/00—Containers, covers, furniture or holders specially adapted for surgical or diagnostic appliances or instruments, e.g. sterile covers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B50/00—Containers, covers, furniture or holders specially adapted for surgical or diagnostic appliances or instruments, e.g. sterile covers
    • A61B50/30—Containers specially adapted for packaging, protecting, dispensing, collecting or disposing of surgical or diagnostic appliances or instruments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/16—Holders for containers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3847—Multimodal interactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B01D15/426—Specific type of solvent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

ELUTION OF BIOMOLECULES FROM MULTI-MODAL RESINS USING MES AND MOPS AS MOBILE PHASE MODIFIERS The present invention relates to methods for purifying or enriching a biomolecule using multimodal resins and an elution buffer containing a Good's buffer. [Figure 1]
SG10201901695RA 2012-10-24 2013-10-23 Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers SG10201901695RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261717880P 2012-10-24 2012-10-24

Publications (1)

Publication Number Publication Date
SG10201901695RA true SG10201901695RA (en) 2019-03-28

Family

ID=49554488

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201901695RA SG10201901695RA (en) 2012-10-24 2013-10-23 Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers
SG11201502918RA SG11201502918RA (en) 2012-10-24 2013-10-23 Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201502918RA SG11201502918RA (en) 2012-10-24 2013-10-23 Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers

Country Status (10)

Country Link
US (2) US20150275195A1 (en)
EP (1) EP2911759B1 (en)
CN (3) CN105777862A (en)
AU (3) AU2013334644B2 (en)
CA (1) CA2888824C (en)
DK (1) DK2911759T3 (en)
HK (1) HK1222868A1 (en)
MX (1) MX2015005313A (en)
SG (2) SG10201901695RA (en)
WO (1) WO2014066471A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105777862A (en) * 2012-10-24 2016-07-20 建新公司 Elution of biomolecules from multi-modal resins using MES and MOPS as mobile phase modifiers
SG10201709131UA (en) 2013-03-08 2017-12-28 Genzyme Corp Continuous purification of therapeutic proteins
TWI709570B (en) 2014-01-17 2020-11-11 美商健臻公司 Sterile chromatography and manufacturing processes
TWI709569B (en) 2014-01-17 2020-11-11 美商健臻公司 Sterile chromatography resin and use thereof in manufacturing processes
CA3084827A1 (en) * 2017-12-29 2019-07-04 Baxalta Incorporated Adeno-associated virus purification methods
CN108479110A (en) * 2018-04-10 2018-09-04 深圳市菲鹏生物制药股份有限公司 A kind of cell culture liquid decolorizer and discoloration method
CA3110666A1 (en) 2018-08-31 2020-03-05 Genzyme Corporation Sterile chromatography resin and use thereof in manufacturing processes
DE102020214647A1 (en) 2020-11-20 2022-05-25 DIL Deutsches Institut für Lebensmitteltechnik e.V. Anthocyanin-containing extract powder and method of manufacture

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4347322A (en) * 1981-01-12 1982-08-31 Nabisco Brands, Inc. Chromatographic process for enzyme purification
US4663288A (en) * 1985-05-22 1987-05-05 Nabisco Brands, Inc. Process for purification of enzymes
HU230275B1 (en) 1996-09-13 2015-11-30 Shire Human Genetic Therapies, Inc Method for producing purified human alpha galactosidase a compositions; pharmaceutical compositions comprising said purified compositions for use in treating disorders originating from alpha galactosidase a deficiency
EP1866427A4 (en) * 2005-03-30 2010-09-01 Novo Nordisk As Manufacturing process for the production of peptides grown in insect cell lines
US20080090278A1 (en) * 2006-03-31 2008-04-17 Toyo Boseki Kabushiki Kaisha Method for enhancing stability of a composition comprising soluble glucose dehydrogenase (gdh)
PL2167526T3 (en) 2007-07-11 2011-09-30 Novo Nordisk As Purification of factor viii using a mixed-mode or multimodal resin
WO2009092014A1 (en) * 2008-01-18 2009-07-23 Gagnon Peter S Enhanced purification of antibodies and antibody fragments by apatite chromatography
JP5619738B2 (en) 2008-06-24 2014-11-05 オクタファルマ アクチェンゲゼルシャフト Method for purifying coagulation factor VIII
US20110166332A1 (en) 2008-09-12 2011-07-07 Ge Healthcare Bio-Sciences Ab Enhanced antibody aggregate removal with capto adhere in the presence of protein-excluded zwitterions
CA2697999C (en) * 2009-04-24 2013-04-30 Werner Hoelke A stabilized aqueous alpha-galactosidase composition and methods relating thereto
US20120208986A1 (en) * 2009-10-20 2012-08-16 Wenger Marc D Use of mixed mode chromatography for the capture and purification of basic antibody products
US8951807B2 (en) * 2010-01-15 2015-02-10 Bio-Rad Laboratories, Inc. Surface neutralization of apatite
WO2011121020A1 (en) 2010-03-30 2011-10-06 Octapharma Ag A process for purifying vitamin k dependent proteins such as coagulation factor ix
RU2015149979A (en) * 2010-03-30 2019-01-15 Октафарма Аг METHOD FOR CLEANING PROTEIN OF GROWTH FACTOR
US9422329B2 (en) * 2010-11-05 2016-08-23 Hoffmann-La Roche Inc. Optimized method for antibody capturing by mixed mode chromatography
EP2638156B1 (en) * 2010-11-09 2016-01-27 Qiagen GmbH Method and device for isolating and purifying double-stranded nucleic acids
CN103732610A (en) * 2011-06-13 2014-04-16 默沙东公司 Methods of purification of native or mutant forms of diphtheria toxin
BR112014010406A2 (en) 2011-11-02 2017-04-25 Genentech Inc overload and elute chromatography
CN105777862A (en) * 2012-10-24 2016-07-20 建新公司 Elution of biomolecules from multi-modal resins using MES and MOPS as mobile phase modifiers
EA032680B1 (en) * 2012-11-13 2019-07-31 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. PURIFICATION OF RECOMBINANT HUMAN GALACTOCEREBROSIDE β-GALACTOSIDASE (rhGALC)
TWI631132B (en) * 2013-05-06 2018-08-01 賽諾菲公司 Continuous multistep process for purifying antibodies

Also Published As

Publication number Publication date
DK2911759T3 (en) 2024-09-16
EP2911759A1 (en) 2015-09-02
AU2018241214A1 (en) 2018-11-01
CN105777862A (en) 2016-07-20
MX2015005313A (en) 2016-04-06
CA2888824C (en) 2021-02-02
AU2013334644A1 (en) 2015-05-07
AU2020203008A1 (en) 2020-05-28
AU2013334644B2 (en) 2018-07-12
WO2014066471A1 (en) 2014-05-01
HK1222868A1 (en) 2017-07-14
EP2911759B1 (en) 2024-07-17
AU2018241214B2 (en) 2020-02-06
CN104884147A (en) 2015-09-02
CN111172135A (en) 2020-05-19
CA2888824A1 (en) 2014-05-01
SG11201502918RA (en) 2015-05-28
AU2020203008B2 (en) 2022-06-16
AU2018241214B9 (en) 2020-02-20
US20150275195A1 (en) 2015-10-01
US11203747B2 (en) 2021-12-21
US20200131493A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
SG10201901695RA (en) Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers
MX354243B (en) Antibody polypeptides that antagonize cd40.
MX336682B (en) Antibodies against human csf-1r and uses thereof.
MX356337B (en) Antibodies against human csf-1r and uses thereof.
HK1208476A1 (en) Anti-b7-h6 antibody, fusion proteins, and methods of using the same b7-h6
WO2014189973A3 (en) Anti-transferrin receptor antibodies and methods of use
PH12014502767A1 (en) Interleukin-2 fusion proteins and uses thereof
TN2014000438A1 (en) Anti-fcrn antibodies
PH12014501108A1 (en) Anti-il-36r antibodies
MX358367B (en) Low affinity blood brain barrier receptor antibodies and uses therefor.
PH12014502406A1 (en) Anti-il-23p19 antibodies
WO2012064836A9 (en) Methods and compositions for neural disease immunotherapy
WO2014083162A3 (en) Method for preparing an optionally functionalised glass having bimodal porosity, and said glass
WO2013149111A3 (en) Anti-tlr4 antibodies and uses thereof
HK1213262A1 (en) Process for the preparation of 1-([1,3]dioxolan-4-ylmethyl)-1h- pyrazol-3-ylamine 1-([13]-4-)-1h--3-
MX336369B (en) Use of ellagic acid as an anti-dandruff agent.
HK1215244A1 (en) Process for the preparation of (1s,4s,5s)-4-bromo-6- oxabicyclo[3.2.1]octan-7-one (1s4s5s)-4--6-[321]-7-
WO2013093627A3 (en) In silico affinity maturation
MX2015014935A (en) Method of synthesising adcs using affinity resins.
WO2014064712A3 (en) An improved process for the preparation of fulvestrant
WO2014122079A3 (en) Improved purification of proteins via a deglycosylation step
WO2013011062A3 (en) Antagonistic antibodies against oscar
EP3838881C0 (en) Method of synthesizing 6-(5-ethoxyhept-1-yl)bicyclo[3.3.0]octan-3-one
Lee Interacive Game Control Interface Using SmartPhone
HUP1000515A2 (en) Novel affinity surface for the purification of proteins, its production and use